CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta‐analysis of randomized clinical trials

This study aimed to evaluate the efficacy and safety of personalized genotype‐guided selection of antiplatelet therapy versus standard of care in patients undergoing percutaneous coronary intervention (PCI).

[1]  Deepak L. Bhatt.  Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? , 2009, JAMA.

[2]  G. Stouffer,et al.  Clinical Outcomes and Sustainability of Using CYP2C19 Genotype–Guided Antiplatelet Therapy After Percutaneous Coronary Intervention , 2018, Circulation. Genomic and precision medicine.

[3]  Edward O'Brien,et al.  Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial , 2012, The Lancet.

[4]  M. Tomaniak,et al.  Can prasugrel decrease the extent of periprocedural myocardial injury during elective percutaneous coronary intervention? , 2017, Polish archives of internal medicine.

[5]  J. Meer,et al.  The Influence of NSAIDs on Coumarin Sensitivity in Patients with CYP2C9 Polymorphism After Total Hip Replacement Surgery , 2012, Molecular Diagnosis & Therapy.

[6]  D. Angiolillo,et al.  Platelet Function Testing in Contemporary Clinical and Interventional Practice , 2014, Current Treatment Options in Cardiovascular Medicine.

[7]  D. Angiolillo.  Dual antiplatelet therapy guided by platelet function testing , 2017, The Lancet.

[8]  Diego Ardissino,et al.  Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial. , 2018, Journal of the American College of Cardiology.

[9]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[10]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[11]  Hong-Guang Xie,et al.  The gain‐of‐function variant allele CYP2C19*17: a double‐edged sword between thrombosis and bleeding in clopidogrel‐treated patients , 2012, Journal of thrombosis and haemostasis : JTH.

[12]  R. McPherson,et al.  A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study , 2015, The Pharmacogenomics Journal.

[13]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[14]  Joshua C Denny,et al.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. , 2018, JACC. Cardiovascular interventions.

[15]  Z. Zhong,et al.  Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China , 2017, European Journal of Clinical Pharmacology.

[16]  S. Kong,et al.  Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome , 2016, The Journal of international medical research.

[17]  Xiang Ma,et al.  Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. , 2013, International journal of cardiology.

[18]  Deepak L. Bhatt,et al.  Clopidogrel resistance - a clear problem with an unclear solution. , 2012, Indian heart journal.

[19]  Deepak L. Bhatt,et al.  Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. , 2010, The New England journal of medicine.

[20]  E. Vicaut,et al.  Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial , 2016, The Lancet.

[21]  J. Moon,et al.  Role of genetic testing in patients undergoing percutaneous coronary intervention , 2018, Expert review of clinical pharmacology.

[22]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.

[23]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[24]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[25]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[26]  C. Dávila-Fajardo,et al.  Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent. , 2016, International journal of cardiology.

[27]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[28]  Deepak L. Bhatt,et al.  The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. , 2012, European heart journal.